Clinical trials: Covid19 Vaccine
COVID-19 Vaccines
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
During the study, members of different online and offline communities will be followed post COVID-19 vaccination. Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either…
- Trial name
- NCT04832932
- Testing
- COVID-19 vaccines
- Where
- 5 sites in United States, Georgia and 2 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Mebo Research, Inc.
Covid19
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
This is a Phase 1 clinical trial to assess the safety and immunogenicity of AdCLD-CoV19-1 in healthy adults.
- Trial name
- NCT05047692
- Testing
- AdCLD-CoV19-1
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
Covid19
Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine
This study is a randomized, double-blinded, and active-controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine.
- Trial name
- NCT04942405
- Testing
- TURCOVAC, CoronaVac
- Where
- 29 sites in Turkey (Türkiye)
- Volunteers
- 1,290 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19, Therapeutic Vaccine
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
To date, there is no vaccine or treatment with proven efficiency against COVID-19, and the transmissibility of the SARS-CoV-2 virus can be inferred by its identification in the oro-nasopharynx.
- Conditions
- COVID-19, Therapeutic Vaccine, BCG, SARS-CoV 2
- Trial name
- BATTLE (NCT04369794)
- Testing
- BCG
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- University of Campinas, Brazil
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior.
- Trial name
- NCT04816669
- Testing
- BNT162b2
- Where
- 21 sites in United States
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents
This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive…
- Trial name
- CoVacSpec (NCT05252910)
- Where
- 32 sites in United States, Colombia and 5 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pharm-Olam, LLC
COVID-19, Vaccine Effectiveness Against COVID-19
COVID-19 Effectiveness Study in the Philippines
This is a multi-site, observational, prospective test negative design case-control study which primarily aims to determine the protective effectiveness of 2 doses of an inactivated COVID-19 vaccine at least 14 days after the…
- Conditions
- COVID-19, Vaccine Effectiveness Against COVID-19, Hospitalized COVID-19
- Trial name
- NCT05518760
- Testing
- no intervention
- Where
- Philippines
- Volunteers
- 3,000 people
- Sponsor
- University of the Philippines
Coronavirus Infection, COVID-19
Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
A randomized, double-blind, placebo-controlled, adaptive, seamless phase I / II clinical study of the safety and immunogenicity of a recombinant viral vector AAV5-RBD-S vaccine for the prevention of coronavirus infection…
- Trial name
- COVER (NCT05037188)
- Testing
- Low dose BCD-250 injection, High dose BCD-250 injection, Low dose or high dose BCD-250 injection
- Where
- 2 sites in Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biocad
Herpes Zoster, Allergy and Immunology
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19.
- Conditions
- Herpes Zoster, Allergy and Immunology, Corona Virus Infection
- Trial name
- NH-Shingrix (NCT04523246)
- Testing
- SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
COVID-19 Prevention
An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine
Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers.
- Trial name
- NCT04713488
- Testing
- Sputnik Light
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents
This study is a global multi-center , case-driven, randomized, double-blinded, and placebo-controlled phase Ⅲ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04992260
- Testing
- Inactivated COVID-19 Vaccine, Controlled vaccine
- Where
- 38 sites in Chile, Malaysia and 2 more
- Volunteers
- 11,349 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine
To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesian government has launched "Vaksinasi Gotong Royong" (a mutual cooperation vaccination program) in which any company/legal entity/business entity…
- Trial name
- NCT05126550
- Testing
- SARS-CoV-2 vaccine (Vero cell) inactivated
- Where
- 4 sites in Indonesia
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
COVID-19, SARS-CoV-2 Infection
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18-60 years old…
- Trial name
- NCT06381843
- Testing
- Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
SARS-CoV-2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
This was a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population.
- Trial name
- NCT04649021
- Testing
- BNT162b2
- Where
- China
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV-2 Infection
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT05037097
- Testing
- ARCT-165, ARCT-154, ARCT-021
- Where
- 4 sites in United States, Singapore and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
COVID-19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
The purpose of this study is to assess the immunogenicity and safety of MVC- COV1901 vaccine compared to AZD1222 in heathy adults.
- Trial name
- NCT05198596
- Testing
- MVC-COV1901, AZD1222
- Where
- 2 sites in Thailand
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Healthy
Follow-up Study of Population Vaccinated With COVID-19 Vaccine
A multi-centered clinical follow-up study to investigate the long-term dynamic of COVID-19 antibody level after vaccination.
- Trial name
- NCT04972591
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Qin Ning
COVID-19
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.
- Trial name
- NCT04655625
- Testing
- Group A (AG0302-COVID19), Group B (AG0302-COVID19)
- Where
- 8 sites in Japan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.